03 October 2022 : Clinical Research
Effect of Vitamin D Concentration on Course of COVID-19
Magdalena Dominika Szerszeń12ABDEF*, Aleksandra Kucharczyk3BDEF, Katarzyna Bojarska-Senderowicz3BDEF, Monika Pohorecka32ADEF, Andrzej Śliwczyński4CD, Janusz Engel5C, Tomasz Korcz6B, Dariusz Kosior7A, Irena Walecka8A, Wojciech Stefan Zgliczyński9A, Waldemar Wierzba1011G, Adam Jerzy Sybilski32ADFDOI: 10.12659/MSM.937741
Med Sci Monit 2022; 28:e937741
Table 2 Occurrence of comorbidities in study population.
| Comorbidities | COVID-19 (+) | COVID-19 (−) | ||||
|---|---|---|---|---|---|---|
| Male | Female | Total | Male | Female | Total | |
| Without any comorbidities | 14 | 18 | 32 (17.2%) | 20 | 32 | 52 (16.3%) |
| Diabetes | 0 | 0 | 0 | 2 | 1 | 3 (0.9%) |
| Diabetes + respiratory tract diseases | 0 | 0 | 0 | 0 | 1 | 1 (0.3%) |
| Diabetes + cardiovascular disease | 1 | 0 | 1 (0.5%) | 0 | 4 | 4 (1.3%) |
| Diabetes + other coexisting diseases | 3 | 2 | 5 (2.7%) | 2 | 1 | 3 (0.9%) |
| Diabetes + respiratory tract diseases + other coexisting diseases | 0 | 1 | 1 (0.5%) | 0 | 0 | 0 |
| Diabetes + cardiovascular disease + other coexisting diseases | 11 | 10 | 21 (11.3%) | 18 | 13 | 31 (9.7%) |
| Diabetes + respiratory tract diseases + cardiovascular disease + other coexisting diseases | 7 | 4 | 11 (5.9%) | 10 | 10 | 20 (6.3%) |
| Cardiovascular disease | 7 | 2 | 9 (4.8%) | 14 | 3 | 17 (5.3%) |
| Cardiovascular disease + respiratory tract diseases | 0 | 1 | 1 (0.5%) | 1 | 4 | 5 (1.6%) |
| Cardiovascular disease + other coexisting diseases | 20 | 25 | 45 (24.2%) | 34 | 38 | 72 (22.6%) |
| Cardiovascular disease + Respiratory Tract Disease + other coexisting diseases | 11 | 6 | 17 (9.1%) | 21 | 16 | 37 (11.6%) |
| Respiratory tract diseases | 1 | 0 | 1 (0.5%) | 2 | 0 | 2 (0.6%) |
| Respiratory tract diseases + other coexisting diseases | 4 | 4 | 8 (4.3%) | 5 | 5 | 10 (3.1%) |
| Other coexisting diseases | 14 | 20 | 34 (18.3%) | 34 | 28 | 62 (19.4%) |